|Dr. Denver M. Lough||Chairman, CEO & Chief Scientific Officer||N/A||N/A||1981|
|Mr. Paul Elliot Mann||Chief Financial Officer||N/A||N/A||N/A|
|Dr. Edward Winslow Swanson||Chief Operating Officer||N/A||N/A||1985|
|Mr. Rich Haerle||VP of Investor Relations & Strategy||N/A||N/A||N/A|
|Mr. Cameron J. Hoyler J.D.||Gen. Counsel||N/A||N/A||1984|
PolarityTE, Inc. operates as commercial-stage biotechnology and regenerative biomaterials company in the United States. The company focuses on discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. Its PolarityTE platform would be able to provide transform tissue regeneration, including potential regeneration of multiple tissue substrates, such as skin, bone, muscle, fat, cartilage, nerves, and blood vessels, as well as neural elements, solid and hollow organ composite tissue systems. The company is headquartered in Salt Lake City, Utah.
PolarityTE, Inc.’s ISS Governance QualityScore as of September 1, 2018 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 9; Compensation: 10.